A prospective study examined the sequential effects of diethylstilboestrol (stilboestrol) on sodium balance, cardiac state, and renin-angiotensin-aldosterone activity in six patients with metastatic carcinoma of the prostate. Whereas metabolic balance studies did not show evidence of sodium retention during the first seven days of treatment, there was a significant and progressive increase in plasma volume after three months (mean increase 541 ml; p<0-01). Stilboestrol increased supine plasma renin and angiotensin II values but the response of renin-angiotensinaldosterone activity to erect posture was progressively reduced during treatment. No significant changes in blood pressure or indices of cardiac function occurred during the three months of observation.
Introduction
Since the work of Huggins and Hodges hormonal manipulation has been the mainstay treatment of metastatic carcinoma of the prostate. Orally administered oestrogens, usually diethylstilboestrol (stilboestrol), however, have been associated with an increased risk of cardiovascular complications from pulmonary emboli, cerebrovascular accidents, myocardial infarction, and congestive cardiac failure.23 Although widely recognised as a clinical problem, the mechanisms underlying the cardiac complications-particularly congestive heart failure and hypertensionhave not been fully elucidated. The present study was designed to assess in detail the sequential effects of stilboestrol on electrolyte balance, renin-angiotensin-aldosterone activity, and cardiac state in a small group of patients with prostatic carcinoma and normal cardiovascular function.
Subjects and methods
Patients beginning hormonal treatment with oral stilboestrol for metastatic carcinoma of the prostate were considered for the study. Criteria for exclusion included a history of congestive heart failure, deep venous thrombosis, pulmonary emboli, hypertension, diabetes, plasma creatinine concentration over 180 kmol/l (2-0 mg/100 ml), or recent major surgery; treatment with any of the following: anti-inflammatory and antiprostaglandin agents, antihypertensives, fi blockers, diuretics, and cytotoxics; and a need for immediate antiandrogen treatment-for example, for disabling bone pain. The protocol was approved by the ethical committee of the Canterbury Hospital Board, and all patients gave informed consent.
STUDY DESIGN
After diagnosis of metastatic carcinoma of the prostate the patients were admitted for metabolic studies before and immediately after beginning stilboestrol. They were given a normal diet according to individual preferences but which for 10 Electrolytes, plasma volume, and cardiac state-There was no consistent effect of stilboestrol on sodium excretion during the 10 days of controlled sodium intake (table II) . Body weight did not change significantly and there were no changes in plasma sodium or potassium concentrations. Table I and figure 1 show the sequential changes in plasma volume over three months of stilboestrol treatment. A mean increase of 541 ml at 90 days was highly significant (p<0 01) when compared with pretreatment values. There was no consistent change in haemodynamic indices in any patient: blood pressure did not increase and there were no significant changes in left ventricular ejection fraction or left ventricular end diastolic volume (table I) .
Hormone changes-Basal supine (8 am) plasma renin activities and angiotensin II concentrations increased within six days after beginning stilboestrol and there was a significant increase in urine aldosterone excretion, though plasma aldosterone did not change (tables II, III). At four and 12 weeks of treatment basal plasma renin activity and angiotensin II concentrations had increased further and were significantly higher than pretreatment values (as was aldosterone at four weeks). Plasma cortisol also increased significantly from the sixth day of treatment (mean 437 nmol/l (15-8 tig/100 ml) before treatment, 810 nmol/l (29-3 ig/100 ml) on day 6, 1213 nmol/l (43 9 Rg/100 ml) on day 30, 1243 nmol/l (45-0 [Lg/100 ml) on day 90; p<001, p<005, p<0 05, respectively). There were no significant changes in plasma arginine vasopressin concentrations during stilboestrol treatment (mean pmol/l (10-4 pg/ml) before treatment, 6-3 pmol/l (6-8 pg/ml) on day 6, 7-1 pmol/l (7 7 pg/ml) on day 30, 5-1 pmol/l (5 5 pg/ml) on day 90). Despite the increases in basal supine hormone concentrations the response of renin-angiotensin-aldosterone activity to erect posture was greatly pain but at one month it was obvious that his disease had advanced. Results at three months were therefore from five patients only. Another patient (case 2) developed angina with effort and was treated with oral glyceryl trinitrate. The remaining patients did not encounter any problems during the study. Compliance in all patients was confirmed by tests for stilboestrol in urine as well as detecting a reduction in plasma testosterone (mean 19-7 (SEM 5-3) nmol/l (5-7 (1-5) ng/ml) before stilboestrol, 1-2 (0-2) rnol/l (0-3 (0-06) ng/ml) at two weeks; p<0 05) and increasing sex 1463 small group of patients without cardiovascular disease and in whom drug interference was minimised.
Our results show clearly that during stilboestrol treatment there is expansion of the plasma volume. There was clear evidence ofearly and sustained activation of the renin-angiotensin-aldosterone system and a definite abnormality in response of this system to erect posture. Unlike a study of postmenopausal women'°and the findings of Johnson and Davis in dogs" our study did not show a direct sodium retaining action of stilboestrol, at least in the short term. If plasma volume increases without change in reabsorption of sodium, oestrogens may be acting to redistribute body fluids so that extracellular fluid volume expands at the expense of intracellular volume. Despite this expansion in plasma volume basal plasma renin activities and angiotensin II concentrations increased rapidly and were sustained above prestudy values for at least three months. While there is good evidence in women that oestrogens increase renin (both renin substrate'2'6 and renin concentration'6), there is less evidence of activation of the renin-angiotensin-aldosterone system in men.'2 A previous study in patients with prostatic cancer '7 showed no change in plasma renin activity during oestrogen 256   442  233  467  600  465  366  594  3  317  619  218  490  184  515  365  379  357  383   4  131  254  116  316  158  305  197  236  184  185  5  116  472  100  408  145  480  122  370  146  388  6  145  252  110  565  82  291  191  377  84  72   Mean  202  463  211  478  163  423  261*  395  227  324  SEM  34  64  56  44  20  27  44  38  57  81 t (fig 2) becomes progressively reduced. Whether this diminution in responsiveness to erect posture is due to the associated plasma volume expansion, direct inhibition ofrenin secretion by higher angiotensin II concentrations, or other mechanisms cannot be determined from our study. Interestingly, most other states of hyperreninaemia are associated with an increased response of renin-angiotensin-aldosterone activity to erect posture.'8 19 The different behaviour of patients treated with oestrogen may follow from the action of oestrogen to increase renin substrate concentrations,'2 ' -whereas in other hyperreninaemic states presumably there is a direct stimulus to renin secretion.
Although our patients showed no sign of cardiac dysfunction or hypertension during stilboestrol treatment, the combination of plasma volume expansion and an increase in plasma angiotensin II and aldosterone concentrations might be hazardous in patients with heart disorders or a tendency to hypertension. The findings of this study suggest an important mechanism of the cardiac complications associated with oestrogen treatment and reaffirm the need carefully to evaluate cardiac and haemodynamic state in patients w.th prostatic cancer before deciding on the form of treatment.
Introduction
Routine follow up of patients after definitive treatment for malignant disease forms a major part of the workload of most radiotherapy and many surgical clinics. Follow up may be for a variety of reasons, including assessing the efficacy of treatment and its morbidity, helping patients to come to terms with their illness, teaching, and, especially for less common conditions, gaining an understanding of the clinical course of the disease. The main purpose offollow up, however, is to detect relapse at a stage at which effective secondary management can be begun, and it is this that generally determines the frequency of attendance. Though some patients undoubtedly find follow up reassuring, many others find it a considerable source of stress. Regular attendance is costly not only for the patient, who may have to pay for transport or take time off work, but also in terms of the use of National Health Service resources.
The value of routine follow up has been questioned,' but few studies have examined the effectiveness of follow up in detecting relapse and what influence, if any, this has on a patient's subsequent clinical course.4 Breast cancer is the most common malignancy in women, and this study examined the value of routine follow up of women after primary treatment for early breast cancer by mastectomy alone or by mastectomy and postoperative radiotherapy.
Patients and methods
During 1974-7 inclusive 717 women were referred to this department with a diagnosis of carcinoma of the breast, which was clinically staged as
